Enrollment begins in Elan’s ELND005 Phase 2 trial for agitation/aggression associated with AD

Elan Corporation, plc (NYSE: ELN) today announced that it has enrolled the first patient in a Phase 2 clinical trial of ELND005 (Study AG201) for the treatment of agitation/aggression in patients with moderate to severe Alzheimer's disease (AD).

"Agitation/Aggression are common and distressing neuropsychiatric symptoms (NPS) of AD. These symptoms are a leading cause of patients being placed in nursing homes," said Dr. Bruno Vellas, MD PhD, Chairman of Internal and Geriatric Medicine at University Hospital Toulouse, France and Principal Investigator of the European Alzheimer's Disease Consortium. "Approximately 90% of AD patients develop NPS, and up to 60% develop agitation/aggression over the course of their disease. With no approved therapies for agitation/aggression in most countries, including the US, it is a major treatment problem in AD. This trial is an important step in providing a potential therapy to help manage these symptoms."

"We believe ELND005 has opportunities in symptomatic neuropsychiatric indications based on its potential beneficial effects coupled with a good understanding of its safety profile from earlier clinical trials in AD." said Dr. Menghis Bairu, Chief Medical Officer and Head of Development at Elan. "Symptomatic treatments are important in AD patient care, especially at the advanced stages of disease. As patients advance in their AD, there is an increase in both the prevalence and severity of agitation/aggression."

Dr. Bairu added "From a development perspective, given the significant unmet need in this patient group, we believe that potential beneficial effects on agitation/aggression will provide a meaningful advance in patient management."


Elan Corporation, plc


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
You might also like... ×
Loyola participating in landmark study to examine use of PET scans to detect Alzheimer’s disease